{"id":"W4405045778","doi":"10.1182/blood-2024-201624","title":"Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Brentuximab vedotin; Medicine; Nivolumab; Internal medicine; Oncology; Ipilimumab; Refractory (planetary science); Hodgkin lymphoma; Randomized controlled trial; Adverse effect; Phases of clinical research; Lymphoma; Clinical trial; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001459331,0.000886417,0.001482737,0.0002792495,0.0003520845,0.0005937613,0.0004535937,0.0006827221,0.00215543],"category_scores_gemma":[0.001526069,0.0004464447,0.0008727458,0.0003423223,0.0009437438,0.0005769685,0.0003568568,0.001609166,0.0003495932],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007853486,"about_ca_system_score_gemma":0.001199825,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005701143,"about_ca_topic_score_gemma":0.001057925,"domain_scores_codex":[0.999255,0.0004350104,0.00004213145,0.00009797761,0.00007081831,0.00009897496],"domain_scores_gemma":[0.9987879,0.0002873025,0.000361308,0.00008661834,0.00005276076,0.0004240242],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.800647,0.02116638,0.09985013,0.0004414443,0.001717841,0.0005729722,0.0002996826,0.001434445,0.01336225,0.0001575098,0.001912052,0.05843838],"study_design_scores_gemma":[0.3938465,0.4752666,0.1205303,0.0000585236,0.001221706,0.001204242,0.000181859,0.001513778,0.00292739,0.0002364271,0.002979015,0.0000338409],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982862,0.0006287971,0.0001181079,0.00008423287,0.00002128811,0.0003242359,0.0002610676,0.00001052188,0.0002654761],"genre_scores_gemma":[0.996989,0.0006409897,0.0004356915,0.0002927162,0.00009686619,0.0005475263,0.0006968402,0.000006910614,0.0002935611],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00215543,"threshold_uncertainty_score":0.007717788,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006462541439846968,"score_gpt":0.2460965308151292,"score_spread":0.2396339893752822,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}